title: Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells.
abstract: There is no effective treatment for patients with stage IV renal cell cancer (RCC), although the introduction of new therapy is imminent. Cancer gene therapy is currently considered to be one of the most promising therapeutic modalities in the field of cancer treatment. Based on the results of animal studies, vaccination using autologous granulocyte-macrophage colony-stimulating factor-transduced renal cancer cells appears promising. Before initiating a clinical study using an ex vivo gene-transduced autologous cell vaccine-based immunogene therapy for RCC in Japan, in 1992 we initially planned a Japanese version of a clinical protocol in collaboration with a US group. In 1993, the original protocol was refined. We performed five preclinical qualification studies using RCC nephrectomy specimens from patients in 1997, and the results showed that preparation of RCC cells for autologous vaccines at the Clinical Cell Technology Facility, Research Hospital of the Institute of Medical Science, University of Tokyo, was feasible. Subsequently in August 1998, the Ministry of Health and Welfare and the Ministry of Education, Science, Culture, and Sport approved our clinical protocol. We have recruited two patients with stage IV RCC to our study so far. Here we report the background to the initiation of cancer gene therapy in Japan.
authors.affiliation: Institute of Medical Science, University of Tokyo, Japan. taniken@ims.u-tokyo.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Tani
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazaki
authors.forename: H
authors.initials: H
authors.lastname: Hase
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Azuma
authors.forename: J
authors.initials: J
authors.lastname: Ohata
authors.forename: R
authors.initials: R
authors.lastname: Kitamura
authors.forename: F
authors.initials: F
authors.lastname: Komine
authors.forename: M
authors.initials: M
authors.lastname: Oiwa
authors.forename: A
authors.initials: A
authors.lastname: Masunaga
authors.forename: T
authors.initials: T
authors.lastname: Maekawa
authors.forename: N
authors.initials: N
authors.lastname: Satoh
authors.forename: D
authors.initials: D
authors.lastname: Adachi
authors.forename: Y
authors.initials: Y
authors.lastname: Soda
authors.forename: U
authors.initials: U
authors.lastname: Machida
authors.forename: M
authors.initials: M
authors.lastname: Endo
authors.forename: T
authors.initials: T
authors.lastname: Yamazaki
authors.forename: K
authors.initials: K
authors.lastname: Watari
authors.forename: A
authors.initials: A
authors.lastname: Tojo
authors.forename: N
authors.initials: N
authors.lastname: Yamashita
authors.forename: S
authors.initials: S
authors.lastname: Tomikawa
authors.forename: M
authors.initials: M
authors.lastname: Eriguchi
authors.forename: H
authors.initials: H
authors.lastname: Hamada
authors.forename: Y
authors.initials: Y
authors.lastname: Wakumoto
authors.forename: K
authors.initials: K
authors.lastname: Hanazawa
authors.forename: K
authors.initials: K
authors.lastname: Okumura
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic
chemical_list: D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor